natgillin/translations-raw huggingface dataset:
Therefore, the CHMP’s view was that, as for Eprex/Erypo, the benefit outweighs the identified risks.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Eprexi/Erypo korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Evista, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Evista korral, ületab Raloxifene Teva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Exelon, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Exeloni korral, ületab ravimi Rivastigmine Actavis kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Exelon, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Exeloni puhul, ületab ravimist saadav kasu ilmnenud riskid.
Therefore, the CHMP’s view was that, as for Exelon, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Exeloni puhul, ületab ravimist saadav kasulikkus ilmnenud riskid.
Therefore, the CHMP’s view was that, as for Exforge, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Exforge korral, on ravimi kasulikkus suurem kui sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Genotropin, the benefit outweighs the identified risk.
Seepärast leidis inimtervishoius kasutatavate ravimite komitee, et nagu Genotropini puhulgi, ületab ravimi kasulikkus väljaselgitatud riski.
Therefore, the CHMP’s view was that, as for Glivec, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Gliveci korral, ületab ravimi Imatinib Accord kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Glivec, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Gliveci korral, ületab ravimi Imatinib Actavis kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Glivec, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Gliveci korral, ületab ravimi Imatinib Teva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Glivec, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Gliveci korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for GONAL-f, Ovaleap’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Seetõttu otsustas inimravimite komitee, et nagu ka ravimi GONAL-f korral, on Ovaleapi kasulikkus suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
Therefore, the CHMP’s view was that, as for GONAL-f, the benefits of Bemfola outweigh the identified risks.
Seetõttu on inimravimite komitee arvamusel, et nagu ka võrdlusravimi GONAL-f korral, ületab ravimi Bemfola kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Humatrope, the benefit outweighs the identified risks.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Humatrope korral, ületab ravimi kasulikkus tuvastatud riskid.
Therefore, the CHMP’s view was that, as for Hycamtin, the benefit outweighs the identified risk.
Seetõttu leidis inimravimite komitee, et nagu ka Hycamtini korral, ületab Potactasoli kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Hycamtin, the benefit outweighs the identified risk.
Seetõttu leidis inimravimite komitee, et nagu ka Hycamtini korral, ületab Topotecan Eagle kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Hycamtin, the benefit outweighs the identified risk.
Seetõttu leidis inimravimite komitee, et nagu ka Hycamtini korral, ületab Topotecan Hospira kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Hycamtin, the benefit outweighs the identified risk.
Seetõttu leidis inimravimite komitee, et nagu ka Hycamtini puhul, ületab Topotecan Actavise kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Hycamtin, the benefit outweighs the identified risk.
Seetõttu leidis inimravimite komitee, et nagu ka Hycamtini puhul, ületab Topotecan Teva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Integrilin, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Integrilini korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Kaletra, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Kaletra korral, ületab ravimi Lopinavir/Ritonavir Mylan kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Keppra, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Keppra korral, ületab Levetiracetam Teva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Keppra, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Keppra korral, ületab ravimi Levetiracetam Actavis Group kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Keppra, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Keppra korral, ületab ravimi Levetiracetam Sun kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Keppra, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Keppra korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Lantus, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Lantuse korral, ületab ravimi Abasaglar kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Lyrica, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Lyrica korral, ületab Pregabalin Sandoz GmbH kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Lyrica, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Lyrica korral, ületab Pregabalin Sandoze kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Lyrica, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Lyrica korral, ületab ravimi Pregabalin Accord kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Lyrica, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Lyrica korral, ületab ravimi Pregabalin Mylan kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Lyrica, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Lyrica korral, ületab ravimi Pregabalin Mylan Pharma kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Lyrica, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Lyrica korral, ületab ravimi Pregabalin Zentiva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Micardis, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Micardise korral, on Tolura kasulikkus suurem kui sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Micardis, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Micardise korral, ületab ravimi Telmisartan Activis kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Micardis, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Micardise korral, ületab ravimi Telmisartan Teva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Micardis, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Micardise korral, ületab ravimi Telmisartan Teva Pharma kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for MicardisPlus, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka MicardisPlusi korral, ületab Actelsar HCT kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for MicardisPlus, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka MicardisPlusi korral, ületab Tolucombi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Mimpara, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Mimpara korral, ületab ravimi Cinacalcet Mylan kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Mirapexin, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Mirapexini korral, ületab ravimi Pramipexole Accord kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Neupogen, the benefit outweighs the identified risk.
Seetõttu leidis inimravimikomitee, et nagu ka Neupogeni puhul, ületab Biograstimist saadav kasulikkus ilmnenud riskid.
Therefore, the CHMP’s view was that, as for Neupogen, the benefit outweighs the identified risk.
Seetõttu leidis inimravimikomitee, et nagu ka Neupogeni puhul, ületab Filgrastim ratiopharmist saadav kasulikkus ilmnenud riskid.
Therefore, the CHMP’s view was that, as for Neupogen, the benefit outweighs the identified risk.
Seetõttu leidis inimravimikomitee, et nagu ka Neupogeni puhul, ületab Tevagrastimist saadav kasulikkus ilmnenud riskid.
Therefore, the CHMP’s view was that, as for Neupogen, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Neupogeni korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Neupogen, the benefit outweighs the identified risks and recommended that it be approved for use in the EU.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Neupogeni korral, ületab ravimi Accofil kasulikkus sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
Therefore, the CHMP’s view was that, as for Neupogen, the benefit outweighs the identified risks.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Neupogeni korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for NovoNorm, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka NovoNormi korral, ületab Repaglinide Teva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for NovoNorm, the benefit outweighs the identified risk.
Seetõttu otsustas inimravimite komitee, et nagu ka NovoNormi korral, on Repaglinide Accordi kasulikkus suurem kui sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for NovoNorm, the benefit outweighs the identified risk.
Seetõttu otsustas inimravimite komitee, et nagu ka NovoNormi korral, on Repaglinide Krka kasulikkus suurem kui sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for NovoNorm, the benefit outweighs the identified risk.
Seetõttu otsustas inimravimite komitee, et nagu ka NovoNormi korral, ületab Enyglidi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for other authorised forms of tacrolimus, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka takroliimuse teiste, müügiloa saanud ravimvormide korral, ületab kasulikkus ravimiga kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab Clopidogrel Acino kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab Clopidogrel Acino Pharma GmbH kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab Clopidogrel Acino Pharma kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab Clopidogrel BGR kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab Clopidogrel DURA kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab Clopidogrel Krka kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab Clopidogrel Mylani kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab Clopidogrel Qualimedi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab Clopidogrel ratiopharm GmbH kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab Clopidogrel ratiopharmi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab Clopidogrel Sandozi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab Clopidogrel TADi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab ravimi Clopidogrel Apotexi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab ravimi Clopidogrel HCS kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab ravimi Clopidogrel Teva Pharma B.V. kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab Zyllti kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi puhul, ületab Clopidogrel 1A Pharma kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi puhul, ületab Clopidogrel Hexali kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi puhul, ületab Clopidogrel Teva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi puhul, ületab Grepidi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu Plavixi korral, ületab Clopidogrel Teva Generics B.V. kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Plavixi korral, ületab ravimi Clopidogrel ratiopharm kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Plavixi korral, ületab ravimi Clopidogrel Teva Pharma kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Rebetol, the benefit outweighs the identified risk.
Sel põhjusel arvas inimravimite komitee, et nagu ka Rebetoli korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Rebetol, the benefit outweighs the identified risk.
Sel põhjusel arvas inimravimite komitee, et nagu ka Rebetoli puhul, ületab ravimi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for reference medicine, the benefits of Nordimet outweighs it risks.
Seetõttu on inimravimite komitee arvamusel, et nagu ka võrdlusravimi korral, ületab Nordimeti kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Remicade, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Remicade korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Remicade, the benefit outweighs the identified risks.
Seetõttu oli inimravimite komitee arvamusel, et nagu ka Remicade korral, ületab Inflectra kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Remicade, the benefit outweighs the identified risks.
Seetõttu oli inimravimite komitee arvamusel, et nagu ka Remicade korral, ületab Remsima kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Seretide Diskus, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Seretide Diskuse korral, ületab ravimi kasulikkuse sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Sifrol, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Sifroli korral, ületab Oprymea kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Sifrol, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Sifroli puhul, ületab ravimi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Sustiva, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Sustiva korral, ületab kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Symbicort Turbohaler, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Symbicort Turbohaleri korral, ületab ravimi BiResp Spiromax kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Symbicort Turbohaler, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Symbicort Turbohaleri korral, ületab ravimi Budesonide/Formoterol Teva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Symbicort Turbohaler, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Symbicort Turbohaleri korral, ületab ravimi DuoResp Spiromax kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Symbicort Turbohaler, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Symbicort Turbohaleri korral, ületab ravimi Vylaer Spiromax kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Tamiflu, the benefit outweighs the identified risks.
Seetõttu arvas inimravimite komitee, et nagu ka Tamiflu korral, ületab Ebilfumini kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Taxotere, the benefit outweighs the identified risk.
Honey Lane, Hurley, Maidenhead, SL6 6RJ
Therefore, the CHMP’s view was that, as for Taxotere, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Taxotere korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Temodal, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Temodali korral, ületab Temomedaci kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Temodal, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Temodali korral, ületab Temozolomide Accordi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Temodal, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Temodali korral, ületab Temozolomide Hexali kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Temodal, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Temodali korral, ületab Temozolomide Sandozi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Temodal, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Temodali korral, ületab Temozolomide Suni kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Temodal, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Temodali korral, ületab Temozolomide Teva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Tractocile, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Tractocile korral, ületab ravimi Atosiban SUN kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Velcade, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Velcade korral, ületab Bortezomib Hospira kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Velcade, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Velcade korral, ületab ravimi Bortezomib Suni kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Vfend, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Vfendi korral, ületab ravimi Voriconazole Hospira kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Vfend, the benefit outweighs the identified risks.
Seetõttu arvas inimravimite komitee, et nagu ka Vfendi korral, ületab Voriconazole Accordi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Viagra, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Viagra korral, ületab Sildenafil Actavise kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Viagra, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Viagra korral, ületab Sildenafil ratiopharmi kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Viagra, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Viagra korral, ületab Sildenafil Teva kasulikkus sellega kaasnevad riskid.
Therefore, the CHMP’s view was that, as for Viagra, the benefit outweighs the identified risk.
Seetõttu arvas inimravimite komitee, et nagu ka Viagra korral, ületab Vizarsini kasulikkus sellega kaasnevad riskid.